The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia

被引：2
|
作者：
Carvajal, Luis A. [1 ]
McKeown, Michael R. [2 ]
Hood, Tressa [2 ]
Guo, Linlin [2 ]
Lin, Charles Y. [2 ]
DiMartino, Jorge F. [1 ]
机构：
[1] Kronos Bio Inc, San Mateo, CA USA
[2] Kronos Bio Inc, Cambridge, MA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186605
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
616
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
    Juanjuan Zhao
    Yongping Song
    Delong Liu
    Biomarker Research, 7
  • [2] Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia (vol 7, 19, 2019)
    Zhao, Juanjuan
    Song, Yongping
    Liu, Delong
    BIOMARKER RESEARCH, 2019, 7 (01)
  • [3] Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
    Zhang, Yvyin
    Wang, Peihong
    Wang, Yang
    Shen, Yang
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [4] Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
    Yvyin Zhang
    Peihong Wang
    Yang Wang
    Yang Shen
    Biomarker Research, 11
  • [5] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Masamichi Mori
    Naoki Kaneko
    Yoko Ueno
    Masaki Yamada
    Ruriko Tanaka
    Rika Saito
    Itsuro Shimada
    Kenichi Mori
    Sadao Kuromitsu
    Investigational New Drugs, 2017, 35 : 556 - 565
  • [6] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Mori, Masamichi
    Kaneko, Naoki
    Ueno, Yoko
    Yamada, Masaki
    Tanaka, Ruriko
    Saito, Rika
    Shimada, Itsuro
    Mori, Kenichi
    Kuromitsu, Sadao
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565
  • [7] Differential flt3 mutational status in acute myeloid leukemia predicts sensitivity to flt3 inhibitor gilteritinib in vitro and in vivo
    John, Bincy
    Sundaramoorthy, Pasupathi
    Rainbolt, Elizabeth
    Wong, Andrew
    Ward, Zachary
    Avery, Justin
    Todd, Savannah
    Kidder, Shasta
    Gietl, Diana
    Hall, Chassidy
    Harris, David
    CANCER RESEARCH, 2023, 83 (07)
  • [8] Orally efficacious, selective FLT3 inhibitor for the treatment of acute myeloid leukemia
    Kreutter, Kevin
    Baindur, Nand
    Xu, Guozhang
    Kim, Alexander J.
    Baumann, Christian A.
    Tuman, Robert W.
    Johnson, Dana L.
    Gaul, Micheal D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [9] Gilteritinib (ASP2215), a Novel FLT3/AXL Inhibitor: Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia
    Ueno, Yoko
    Mori, Masamichi
    Kamiyama, Yoshiteru
    Kaneko, Naoki
    Isshiki, Eriko
    Takeuchi, Masahiro
    BLOOD, 2016, 128 (22)
  • [10] An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor
    Kim, Ryan S.
    Yaghy, Antonio
    Wilde, Lindsay R.
    Shields, Carol L.
    JAMA OPHTHALMOLOGY, 2020, 138 (04) : 418 - 419
12345